MAIA net incomeQ3 2026-$7.18M
MAIA net income was -$7.18M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$8.90M a year earlier. For the full fiscal 2025 it was -$22.40M, compared with -$23.25M in fiscal 2024.
MAIA Biotechnology Inc. (MAIA) financials
For the twelve months ended Sep 30, 2026, MAIA Biotechnology Inc. reported -$25.12M of net income.
- Net income, TTM
- -$25.12M
- EPS, diluted, TTM
- -$0.48
- Cash
- $0
- Market cap
- $67.3M
FY2022FY2024
FY2021FY2025
MAIA revenue and earnings growth
MAIA EPSQ3 2026-$0.12
MAIA diluted EPS was -$0.12 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was -$0.70.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | - | $0 | $0 | $0 | - |
| Research and development | $453.7K | $10.01M | $11.11M | $8.93M | $3.50M |
| Selling, general and admin | $9.72M | $6.95M | $9.07M | $6.14M | $4.29M |
| Operating income | -$24.27M | -$16.96M | -$20.18M | -$16.18M | -$7.79M |
| Interest expense | - | $57 | $6.9K | $7.0K | $827.5K |
| Pre-tax income | -$22.39M | -$23.25M | -$19.80M | -$15.80M | -$12.60M |
| Income tax | $2.0K | $2.0K | - | - | - |
| Net income | -$22.40M | -$23.25M | -$19.77M | -$16.22M | -$12.50M |
| EPS, basic | -$0.70 | -$1.05 | -$1.49 | -$1.75 | -$2.37 |
| EPS, diluted | -$0.70 | -$1.05 | -$1.49 | -$1.75 | -$2.37 |
| Diluted shares | 32.1M | 22.2M | 13.3M | 9.3M | 5.3M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $0 | $0 | $7.15M | $10.95M | $10.57M |
| Current assets | $9.70M | $10.15M | $7.56M | $11.81M | $10.67M |
| Total assets | $9.70M | $10.16M | $7.57M | $12.02M | $11.33M |
| Current liabilities | $5.84M | $3.83M | $4.94M | $3.27M | $2.15M |
| Total liabilities | $7.33M | $6.52M | $7.09M | $3.51M | $2.15M |
| Shareholders' equity | $2.38M | $3.63M | $477.5K | $8.51M | $9.18M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$18.84M | -$15.70M | -$13.07M | -$12.10M | -$4.12M |
| Financing cash flow | $17.91M | $18.18M | $9.27M | $12.48M | $14.03M |
| Stock-based compensation | $2.63M | $1.91M | $3.09M | $2.32M | $2.72M |
Key ratios
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $5.34M | $5.64M | $43.7K | -$12.21M | $6.36M | $3.11M | $3.20M | $2.97M | $2.67M | $2.05M | $2.32M | $3.72M |
| Selling, general and admin | $2.69M | $2.68M | $3.42M | $2.44M | $3.00M | $2.06M | $2.23M | $2.04M | $1.52M | $1.76M | $1.63M | $2.66M |
| Operating income | -$8.02M | -$8.32M | -$6.95M | -$4.32M | -$9.36M | -$5.17M | -$5.43M | -$5.00M | -$4.19M | -$3.82M | -$3.95M | -$6.38M |
| Interest expense | - | - | - | - | - | - | - | -$28 | $85 | - | - | $0 |
| Income tax | - | - | $339 | $2.0K | $0 | $0 | $0 | $2.0K | $0 | $0 | $0 | - |
| Net income | -$7.18M | -$7.94M | -$6.37M | -$3.63M | -$8.90M | -$5.35M | -$4.52M | -$3.57M | -$2.74M | -$8.88M | -$8.07M | -$6.26M |
| EPS, basic | -$0.12 | -$0.13 | -$0.14 | -$0.09 | -$0.27 | -$0.18 | -$0.16 | - | -$0.11 | -$0.40 | -$0.46 | - |
| EPS, diluted | -$0.12 | -$0.13 | -$0.14 | -$0.09 | -$0.27 | -$0.18 | -$0.16 | - | -$0.11 | -$0.40 | -$0.46 | - |
| Diluted shares | 60.9M | 60.8M | 45.2M | - | 33.2M | 30.3M | 27.7M | - | 23.9M | 22.2M | 17.6M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $8.27M | $7.15M |
| Current assets | $22.10M | $28.24M | $35.32M | $9.70M | $11.75M | $11.04M | $11.86M | $10.15M | $9.24M | $12.02M | $8.70M | $7.56M |
| Total assets | $22.10M | $28.24M | $35.32M | $9.70M | $11.78M | $11.05M | $11.86M | $10.16M | $9.24M | $12.02M | $8.72M | $7.57M |
| Current liabilities | $6.47M | $6.26M | $6.32M | $5.84M | $9.99M | $5.04M | $5.06M | $3.83M | $3.61M | $3.51M | $4.91M | $4.94M |
| Total liabilities | $7.43M | $7.57M | $7.56M | $7.33M | $11.74M | $7.17M | $6.92M | $6.52M | $7.62M | $8.86M | $14.48M | $7.09M |
| Shareholders' equity | $14.67M | $20.68M | $27.76M | $2.38M | $41.7K | $3.88M | $4.94M | $3.63M | $1.62M | $3.16M | -$5.76M | $477.5K |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.31M | -$6.75M | -$5.31M | -$7.02M | -$3.49M | -$4.14M | -$4.20M | -$3.91M | -$3.52M | -$4.68M | -$3.59M | -$3.99M |
| Financing cash flow | $0 | -$65.0K | $31.05M | $4.80M | $4.23M | $3.41M | $5.46M | $4.85M | $626.8K | $7.99M | $4.72M | $5.03M |
| Stock-based compensation | $881.8K | $723.9K | $650.0K | $810.8K | $646.9K | $802.5K | $371.5K | $693.4K | $455.4K | $413.9K | $350.0K | $1.36M |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 3.41 | 4.51 | 5.59 | 1.66 | 1.18 | 2.19 | 2.35 | 2.65 | 2.56 | 3.42 | 1.77 | 1.53 |
Source: XBRL data MAIA Biotechnology Inc. files with the SEC, latest filing dated Nov 9, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
MAIA peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| MAIA | - | - | -$25.12M | - | $67.3M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
MAIA FAQ
5 questionsIs MAIA profitable?
No. MAIA Biotechnology Inc. reported a net loss of $25.12M for the twelve months ended Sep 30, 2026.How much cash and debt does MAIA have?
MAIA Biotechnology Inc. reported $0 in cash and cash equivalents on its most recent balance sheet in SEC filings.What is MAIA earnings per share?
Diluted earnings per share were -$0.48 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.When did MAIA last report financial results?
The latest statements here come from MAIA Biotechnology Inc.'s 10-Q filed on Nov 9, 2026, covering the period ended Sep 30, 2026.Where does this MAIA financial data come from?
Quantisnow builds these statements from the structured XBRL data MAIA Biotechnology Inc. files with the SEC. It is provided for information only and is not investment advice.